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Abstract
Background: The 2011 expanded Prospective Payment System (PPS) and contemporaneous Food and Drug
Administration label revision for erythropoiesis-stimulating agents (ESAs) were associated with changes in ESA use
and mean hemoglobin levels among patients receiving maintenance dialysis. We aimed to investigate whether
these changes coincided with increased red blood cell transfusions or changes to Medicare-incurred costs or sites
of anemia management care in the period immediately before and after the introduction of the PPS, 2009–2011.
Methods: From US Medicare end-stage renal disease (ESRD) data (Parts A and B claims), maintenance hemodialysis
patients from facilities that initially enrolled 100 % into the ESRD PPS were identified. Dialysis and anemia-related
costs per-patient-per-month (PPPM) were calculated at the facility level, and transfusion rates were calculated
overall and by site of care (outpatient, inpatient, emergency department, observation stay).
Results: More than 4100 facilities were included. Transfusions in both the inpatient and outpatient environments
increased. In the inpatient environment, PPPM use increased by 11–17 % per facility in each quarter of 2011 compared
with 2009; in the outpatient environment, PPPM use increased overall by 5.0 %. Site of care for transfusions appeared
to have shifted. Transfusions occurring in emergency departments or during observation stays increased 13.9 % and
26.4 %, respectively, over 2 years.
Conclusions: Inpatient- and emergency-department-administered transfusions increased, providing some evidence for
a partial shift in the cost and site of care for anemia management from dialysis facilities to hospitals. Further exploration
into the economic implications of this increase is necessary.
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Background
Controlling health care costs while providing quality care
for individual patients and for the population as a whole is
a goal of payers such as the Centers for Medicare &
Medicaid Services (CMS). The United States employs a
variety of billing systems for billing for health care services;
two of the main categories are fee-for-service billings, in
which costs for services are billed separately as line items
in environments such as the emergency department (ED),
and bundled payment billings, in which a diagnosis-related
group (DRG) is billed as a set amount for a particular type
of hospitalization (such as an admission for congestive
heart failure). Costs related to end-stage renal disease
(ESRD) patients receiving maintenance dialysis have been
afforded special scrutiny by CMS, since these costs are
vastly disproportionate to ESRD patients’ representation in
the Medicare population. In 2011, CMS introduced the
Prospective Payment System (PPS, or “the dialysis bundle”),
an expanded capitated payment system encompassing a
range of dialysis-related products and services [1]. This
PPS was designed to create incentives for dialysis pro-
viders to control costs, especially for medications such
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as erythropoiesis-stimulating agents (ESAs) used to treat
ESRD-related anemia. In so doing, CMS sought to decrease
overall expenditures associated with the ESRD program by
approximately 2 %. To help ensure that the PPS did not
negatively affect patient care outcomes, CMS contempor-
aneously established the Quality Improvement Program [2];
this was initially designed to protect against the possibility
that hemoglobin levels would drop unduly, although the
metric for hemoglobin below 10 g/dL was later eliminated
following a 2011 Food and Drug Administration ESA label
revision [3].
While the temporal relationship between the introduc-
tion of the PPS and patterns of anemia management has
been partially explored [4–7], the extent to which less
use of ESAs may be associated with more use of red
blood cell (RBC) transfusions or an associated increase in
transfusion-related costs is not fully established. Addition-
ally, because the PPS does not include costs incurred out-
side the outpatient dialysis setting (e.g., those associated
with hospitalization or outpatient transfusion centers), it
is unclear whether costs and sites of care of anemia man-
agement may have partly shifted from one setting to other,
more intensive settings (e.g., the ED).
Accordingly, we sought to examine how use of ESAs,
intravenous (IV) iron, and RBC transfusions, along with
their associated costs to Medicare, changed in the period
immediately before and after introduction of the PPS.
To do so, we used data from 2009 to 2011. At the same
time, we sought to determine whether RBC transfusion
rates were increasing in inpatient, outpatient, or ED set-
tings. We hypothesized that while use of ESAs likely
declined, as shown by others, use of IV iron and RBC
transfusions, along with their associated costs, likely in-
creased; if true, this would likely have the effect of not only
increasing the use of blood products, a limited societal
resource, but also of shifting some of the anemia manage-
ment burden from dialysis providers to the institutions
that administer most RBC transfusions, such as hospitals
[4]. We reasoned that understanding the effects of the PPS
could be important when designing future reimbursement
policies or payment models, such as ESRD-specific ac-
countable care organizations, aimed at controlling costs.
Methods
Subjects and data source
This study used US Medicare ESRD registry files with
Part A and Part B Medicare claims for ESRD patients on
maintenance hemodialysis. As the goal was to study the
potential effects of the PPS, we used data in the period
immediately before and after its introduction, namely
2009–2011 (the last year for which data were available
for analysis). The CMS Medicare ESRD standard analytic
files (SAFs) were used to obtain information on Medicare
patients. Demographic information was obtained from the
Medical Evidence Report (form CMS-2728). Facility infor-
mation was obtained from dialysis claims data. This was a
descriptive study to ascertain whether any important asso-
ciations could be detected; no statistical modeling was
undertaken.
The study population consisted of facilities that enrolled
100 % into the ESRD PPS in 2011 and had Medicare pri-
mary insured ESRD patients with Part A and Part B cover-
age on maintenance dialysis, and patients who dialyzed at
those facilities. Of note, regulations permitted facilities to
transition gradually (25 % per year over 4 years) to the PPS.
The 203 potentially eligible facilities (4.2 % of the total) that
chose this option were excluded from the analysis because
we reasoned that requiring uniformity in the PPS adoption
strategy would yield the most informative analysis. Facilities
were also excluded if an ownership change occurred during
the study period (2009–2011). Patients were attributed to
only one facility at which they dialyzed most frequently
during each quarter. Patient characteristics across all facil-
ities included age, sex, race, and dialysis duration. Charac-
teristics were calculated at the facility level, with medians
and quartiles of the measured distributions reported. For
example, for age, the median reported represents the value
at which the median age was older at half of the facilities
and younger at half.
Outpatient transfusions and related costs
Using previously published [5, 8] methods, we searched
Medicare claims for outpatient transfusions and related
services, including transfusion-related adverse events.
No attempt was made to determine the specific indication
for transfusion. These services included pre- and post-
transfusion screening (antibody, chemistry, hematology,
immunology) within 3 days before and after the transfusion,
and acquisition and administration of blood products and
storage. We also identified transfusion-related adverse
events, including febrile non-hemolytic reaction, hemolytic
reaction, air embolism, phlebitis, hyperkalemia, allergic
reaction, congestive heart failure (CHF), transfusion-related
lung injury, and transfusion related circulatory overload [8],
within 3 days of the transfusion and delayed hemolytic
reaction within 45 days. CHF hospitalizations were in-
cluded as adverse events only for patients with no other
CHF-related episodes in the 6 months before the trans-
fusion. Transfusion-related costs represented Medicare-
reimbursed amounts on claims for transfusions and
transfusion-related services, and were attributed to a
facility through the patients attributed to that facility. Out-
patient dialysis-related Medicare-reimbursed amounts in-
cluded only those accrued at the facility to which patients
were attributed (i.e., infrequent dialysis treatments at a dif-
ferent facility were not included as costs to the patient’s at-
tributed facility). However, Medicare-reimbursed amounts
for all outpatient transfusions and complications requiring
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hospitalization that occurred at other facilities were attrib-
uted to the patient’s attributed facility. Outpatient dialysis-
related Medicare-reimbursed amounts included composite
rate and the injectable medications ESAs, IV iron, IV vita-
min D, and IV antibiotics. Medicare-reimbursed amounts
were summed quarterly on a facility level, as was total
patient time at risk for accruing costs, and a per-patient-
per-month (PPPM) cost to Medicare was calculated for
each facility for each quarter. Quarterly amounts were
adjusted to December 2011 dollars using the Medical
Consumer Price Index [9].
Anemia management
Information on ESAs and IV iron doses was obtained
from Medicare claims. Hemoglobin concentrations were
obtained from monthly outpatient dialysis claims, and
during each month and quarter we calculated the percent-
age of patients at each facility with at least one reported
hemoglobin concentration below 10 g/dL.
Anemia management measures were calculated on a
facility level, so the distribution of facility-level summary
measures is presented. For example, for mean IV iron dose,
the median represents the value at which the mean dose
was higher at half of the facilities and lower at half. Simi-
larly, for the percentage of patients whose hemoglobin con-
centrations were below 10 g/dL, the median represents the
value at which the percentage was higher at half of the
facilities.
Site of service
To ascertain evidence of a shift in site of care for RBC
transfusions, claims for outpatient transfusions were cate-
gorized as from three sites of service: the ED, observation
stays, and all other outpatient sites. ED visits were identi-
fied using revenue center codes 0450-0459 and 0981 on
outpatient claims. Observation stays were identified using
Healthcare Common Procedure Coding System codes
G0378 and G0379 and revenue center codes 0760 and
0762. Unlike the previous measures, transfusion rates
were calculated across all patients included in the analysis,
not at the level of the facility; this was done to more
clearly investigate rates as they related to site of service,
regardless of the practice patterns of the dialysis facilities
at which patients were dialyzing. The overall PPPM num-
ber of transfusions by site (including inpatient transfu-
sions) represents the total number of transfusion claims
during the quarter across all patients divided by the total
patient time at risk during the quarter. This approach
allows for more direct comparison of the sites of transfu-
sions not occurring at the outpatient dialysis facility.
We applied to and received approval from the Human
Subjects Research Committee of the Hennepin County
Medical Center/Hennepin Healthcare System, Inc.
Results
Facility characteristics
For each quarter of 2009 through 2011, between 4141
and 4425 dialysis facilities (representing 70.6 %-75.4 % of
all dialysis facilities) met eligibility criteria with at least
10 eligible patients. Characteristics of patients at these
facilities are displayed in Table 1. In general, characteris-
tics of facilities and the patients they served remained
relatively constant over the study period. Facilities were
similar regarding age and sex. The race distribution, how-
ever, varied substantially across facilities; the twenty-fifth
and seventy-fifth percentiles of white patients ranged from
32.6 % to 86.6 %.
Overall medicare costs
The distribution of total PPPM Medicare reimbursement
for dialysis-related services is illustrated in Fig. 1. With the
introduction of the PPS, reimbursement amounts for inject-
able medications decreased, by definition, to zero. Median
payment to facilities decreased slightly when adjusted for
Table 1 Distribution of characteristics among the US dialysis
facilities that opted in to the revised prospective payment system,
first quarter of 2009 and last quarter of 2011
Quarter and Year
Characteristics Q1 2009 Q4 2011
Number of facilities 4141 4363
Number eligible patients per facility
Mean across facilities 49.12 47.05
25th percentile 28 27
Median 44 42
75th percentile 63 61
Median age of eligible patients per facility, years
25th percentile 60.0 60.5
Median 64.0 64.0
75th percentile 67.5 68.0
Percentage of female patient per facility
25th percentile 40.0 40.0
Median 45.7 45.7
75th percentile 51.4 51.5
Percentage of white patient per facility
25th percentile 33.3 32.6
Median 63.6 62.5
75th percentile 86.6 85.7
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inflation (even with a simultaneous increase in the PPS
composite rate), and Medicare-reimbursed amounts for
outpatient transfusions and related activities were also rela-
tively stable over the study period, increasingly slightly from
$5.20 ± $11.51 per patient per month in Q1 2009 to $5.68
± 13.71 in Q4 2011. Taking Q1 2011 as an example, we
found the mean amount reimbursed for acquisition and
administration to be $391, for screening and monitoring
$113, and for the adverse events specified above $20, for a
total of $524, a sum that changed little regardless of the
quarter analyzed. While this is somewhat lower than previ-
ously reported [8], those investigators used data from em-
ployer group health plans, which are likely to reimburse at
higher rates than Medicare.
Anemia management
The distribution of mean epoetin alfa (EPO) dose PPPM
administered per facility declined steadily from the second
quarter of 2010 (median 70,317 units) to the end of 2011
(median 42,769 units; Fig. 2a). The pattern of median
PPPM number of IV iron administrations per facility
increased from 2.37 in 2010 Q4 to 2.66 and 3.06 during
the initial two quarters of the PPS (2011 Q1 and Q2), but
then decreased in the last two quarters of 2011 to 2.92
and 2.63, respectively; concurrently, the distribution of
mean dose PPPM administered per facility declined dur-
ing the entire study period (Fig. 2b). Among patients
receiving IV iron, the median dose per quarter dropped
from 875 mg in Q4 2010 to 650 mg in Q4 2011 (data not
shown). The distribution of mean monthly hemoglobin
concentrations declined over time from 11.54 g/dL
(twenty-fifth, seventy-fifth percentiles, 11.3, 11.8) in
January 2009 to 10.76 g/dL (10.4, 11.1) in December
2011. The distribution of the percentage of patients
with hemoglobin concentrations below 10 g/dL at each
facility increased from a median of 9.4 % to 18.2 %
(Fig. 2c).
Frequency of transfusions and site of service
The number of inpatient transfusions appeared to be higher
in 2011 than in 2009 or 2010 (Fig. 3), as did the number of
outpatient transfusions (Table 2). Compared with the first
quarter of 2009, the median of the distribution of the PPPM
number of inpatient transfusions per facility was between
11 % and 17 % higher in each quarter of 2011, and the
median percentage of patients per facility with at least one
inpatient transfusion was between 7 % and 13 % higher in
2011 than in Q1 of 2009. (Of note, because reimbursement
to inpatient facilities is based on the DRG system, we could
not measure costs associated with transfusions occurring in
the inpatient setting.)
An additional analysis was conducted to more precisely
determine the site of outpatient transfusions (e.g., in the
ED, during an observation stay, or in another outpatient
setting); this is shown in Table 2. The number of transfu-
sions in the ED increased by 0.14 per 1000 patient-
months, in the observation stay environment by 0.25 per
1000 patient months, in other outpatient environments by
0.13 per 100 patient-months, and in the inpatient setting
by 2.41 per 1000 patient-months. Although the number of
overall outpatient transfusions PPPM increased slightly
(5.0 %) from Q1 2009 to Q4 2011, the increase was 13.9 %
in the ED and 26.4 % during an observation stay. Because
observation stay and ED transfusions represent only
19.2 % of all outpatient transfusions during the study
period, these increases did not translate into significant
outpatient transfusion cost increases.
Fig. 1 Per person per month adjusted total costs for outpatient dialysis and related injectable medications in US dialysis facilities that opted in to
the revised prospective payment system, 2009–2011
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Discussion
In this study, we sought to examine how the introduction
of the expanded PPS and the ESA label change were associ-
ated with temporal changes in the patterns of ESA, IV iron,
and RBC transfusion use, and to examine the costs and
sites of care associated with anemia management in the
period immediately before and after adoption of the PPS
and the label change. This is an important issue; costs saved
under the capitated PPS system, such as those for transfu-
sions, could be shifted to hospitals because under the DRG
system a hospital receives no additional payment, beyond
that specified by the DRG, for a blood transfusion.
Fig. 2 Distribution of facility-level anemia management parameters among patients dialyzing in US dialysis facilities that opted in to the revised
prospective payment system, 2009–2011. Panel a, epoetin alfa per person per month dose per facility; panel b, intravenous iron per person per month
dose per facility; panel c, hemoglobin concentrations per facility (black line, percentage of patients with hemoglobin concentrations < 10 g/dL at the
facility; grey line, mean hemoglobin concentration, in g/dL, per facility)
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Overall Medicare payments to outpatient dialysis facil-
ities for dialysis-related services declined on a PPPM basis
from 2009 (pre-bundle) through 2011 (post-bundle), a
finding consistent with previous work [10]. However, we
also found increasing use of transfusions in the inpatient
and, especially, observation stay and ED settings. Overall,
these changes were modest, increasing by 0.25 per 1000
patient-month or less in the ED or during observation
stays. Nevertheless, this phenomenon may represent a
shift in the costs and sites of care for anemia management
from the dialysis unit to more the expensive hospital-
based care environment.
Collectively, it appears that the introduction of the PPS
and the ESA label change have been associated with
changes in anemia management in important ways. Pa-
tients dialyzing at the facilities we studied had lower
hemoglobin concentrations on average, and more patients
had concentrations below the threshold of 10 g/dL at any
given time, findings noted by others [6, 7, 11, 12] that are
likely due to changes in patterns of anemia-related medi-
cation use. Our study cannot determine whether this
represents an improved treatment approach compared
with approaches used before the PPS; indeed, results from
clinical trials indicate that lower hemoglobin levels are as-
sociated with lower risk of cardiovascular events [13, 14].
Collectively, these findings suggest that an ESA-sparing
anemia-management strategy resulting in lower mean
hemoglobin levels might be the best overall approach for
dialysis patients, even if it results in a modest increase in
transfusion rates.
The present findings should be considered in the context
of transfusion trends occurring in the general population.
As of 2011, there was an excess of whole blood and
RBC transfusions in the US of about 5.2 % [15], a trend that
appears likely to continue [16]. Overall, whole blood and
RBC transfusions decreased nationally by 8.2 % in 2011
compared with 2008. Given this trend, the relative increase
in transfusions in dialysis patients may be somewhat greater
than it initially appears. It is very unlikely, however, that
changes in transfusion practices in dialysis patients could
seriously tax national blood reserves.
Thus, it is appropriate for society to debate how to opti-
mally use this resource. This is especially true when alterna-
tive treatments are available that can partially ameliorate
the condition (e.g., ESAs or IV iron) [17]. Additionally,
transfusions are not without risk, as they are associated
with inflammatory responses (which may in turn exacer-
bate other conditions) [18], sensitization (which increases
the difficulty of obtaining matches for organ transplant)
[19], transmission of blood-borne diseases [20], and, likely,
Fig. 3 Red blood cell transfusion rates, by site of service among patients dialyzing in US dialysis facilities that opted in to the revised prospective
payment system, 2009–2011
Table 2 Number of transfusions per 1000 patient-months among patients dialyzing in US dialysis facilities that opted in to the revised
prospective payment system, 2009–2011, by site of transfusion service
Quarter and Year
Service Site 2009 Q1 2009 Q4 2010 Q1 2010 Q4 2011 Q1 2011 Q4
Emergency department 0.99 (-) 0.92 (-7.4) 0.98 (-1.0) 0.88 (-10.3) 1.03 (3.7) 1.13 (13.9)
Observation stay 0.94 (-) 0.90 (-3.9) 0.93 (-0.9) 0.98 (4.2) 1.07 (14.4) 1.19 (26.4)
Other outpatient 8.46 (-) 8.11 (-4.1) 8.41 (-0.6) 7.82 (-7.5) 8.59 (1.5) 8.59 (1.6)
Inpatient 21.40 (-) 18.91 (-11.7) 21.00 (-1.9) 21.18 (-1.0) 24.96 (16.6) 23.81 (11.3)
Cell values represent transfusion rate (percentage change from 2009 Q1)
Q calendar quarter
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other infections [21]. When individualizing therapy, these
risks of transfusions should be balanced against the risks of
other therapies. IV iron, for example, constitutes an oxida-
tive stress and may contribute to the inflammatory milieu
characteristic of dialysis patients, while injudicious use of
ESAs has been associated with an increased risk of cardio-
vascular events.
Additionally, an increase in transfusions has implications
for costs and resource use, for which setting is a major
determinant. Transfusions can occur in several settings,
each of which represents a unique clinical environment,
results in different patient experiences, entails specific costs,
and uses different reimbursement mechanisms. That trans-
fusion use increased roughly twice as much in the observa-
tion environment compared with the ED environment may
more generally reflect hospitals increasing use of the obser-
vation stay mechanism [22]. Possibly, hospitals are more
readily transferring patients from the ED to the observation
areas, given that transfusions typically take several hours to
prepare and administer and EDs typically focus on rapid
patient turnaround. However, we cannot be certain that this
is the case.
In the face of increasing overall use of observation
stays, the non-trivial 13.9 % increase in ED transfusions
over the study period invites particularly close scrutiny.
The ED is inherently a suboptimal environment in which
to administer transfusions because it is cost-intensive to
the facility and time- and space-limited. Transfusions
typically require several hours to administer, and even if
administered more quickly while the patient undergoes
acute hemodialysis, the time and resource investment is
substantial in the hyperacute ED setting. As a particularly
expensive site at which to render care, the ED may not be
the most appropriate place to address what may be, at least
in part, a chronic medical issue. Whether EDs are indeed
being used more often for transfusions, or whether patients
are more likely to receive RBC transfusions when they
arrive at an ED with an acute illness with lower mean
hemoglobin concentrations is uncertain, and should be
investigated.
Transfusions that occur in the inpatient setting also have
unique but important cost implications. Inpatient transfu-
sion costs, which are identified under the DRG system,
cannot be directly addressed by our study design. However,
inpatient transfusions represent a cost currently borne by
hospitals. Unless unrecognized cost efficiencies have been
realized in the inpatient RBC transfusion process, hospitals
may be bearing the costs of changes in outpatient manage-
ment if there have been no concomitant changes to the
Medicare DRG-based reimbursement system, effectively
representing cost shifting from dialysis providers and the
Medicare ESRD program to hospitals. However, because we
cannot directly account for inpatient costs with our present
study, we cannot directly demonstrate such cost shifting.
Costs putatively borne by hospitals appear to be more
than offset by overall savings to Medicare. As has been
demonstrated by a US Government Accountability Office
report and in several recent publications, the new PPS,
coupled with the 2011 ESA label revision by the US Food
and Drug Administration, resulted in an approximately
25 % reduction in ESA use compared with pre-2011 levels,
similar to our estimates [23, 24]. Our findings regarding
the association of the PPS and ESA label change with
patient hemoglobin concentrations and RBC transfusion
rates are also broadly concordant with the literature, and
with CMS’ own claims-monitoring data and data from the
US Renal Data System, namely an increase in the rate of
RBC transfusions by 25 to 40 % (despite fluctuations
driven by the completeness of the available information), a
decline in facility-wide hemoglobin concentrations, and
an increase in the percentage of patients with hemoglobin
concentrations below 10 g/dL. While prior work has pro-
vided important estimates of the payer burden associated
with outpatient RBC transfusions, including costs associ-
ated with monitoring, laboratory testing, and associated
complications, it has not fully considered the effects of the
bundle or the ESA label change on outpatient transfusion
costs on a PPPM basis. Such costs, although publicly avail-
able via Medicare facility cost reports, which include finan-
cial data related to provider costs, revenues, and operating
margins, are available only in raw format with minimal
levels of analytical processing [25]. While ESAs, iron, and
transfusions are complementary therapies for anemia man-
agement, each has its own unique risks and benefits. A
growing tolerance for lower mean hemogloblin levels in
dialysis patients likely resulted in non-trivial overall savings
for Medicare, when the effects of the PPS, the Quality
Improvement Program withholds, and other factors are
taken into account.
Of note, we made no attempt to ascertain the specific
indication for transfusions. This would be a challenging
exercise, since a transfusion may occur in the setting of an
acute exacerbation of another disease (such as a cardiac or
pulmonary disorder), which may be coded as the principal
reason for seeking treatment. As such, we cannot deter-
mine precisely why a given patient receives a transfusion.
This does not, however, undermine our finding that trans-
fusions have increased in the ED, observation, and inpatient
settings. Possibly, patients who present to these settings
with, on average, lower hemoglobin levels than in the past
receive transfusions from providers who are less tolerant of
anemia than nephrologists, for whom management of sub-
stantial anemia is a routine clinical occurrence.
Our study is subject to a number of important limita-
tions. Our data are observational, so granular patient
detail is lacking. Additionally, in more recent years,
transfusion rates appear to have declined from a peak
after the PPS. This could be due to providers’ increasing
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confidence, experience, and familiarity with lower mean
hemoglobin levels in dialysis patients, or to providers
adapting to hospital-led initiatives to limit blood transfu-
sions. Thus, our work may not be predictive of the future
transfusion landscape for dialysis patients. Also, billing
claims are an imperfect source from which to determine
how medical care (including transfusions) is rendered,
since they are designed to capture the payment, rather
than strictly clinical, aspects of care. Even so, we followed
previously published methodology where possible [5, 8].
While it is possible that additional transfusion-related
adverse events may have been recorded in 2011 relative to
2010 because of the increase in the fields available for
International Classification of Diseases, Ninth Revision,
Clinical Modification diagnosis codes from 10 to 25, the
adverse events we examined were of substantial clinical
significance, and as such unlikely to occupy positions
below the top 10. Additionally, as stated, we cannot dir-
ectly measure inpatient transfusion costs borne by the
hospital, so it is uncertain whether these costs have indeed
increased; to fully understand the payer impact of a rise in
inpatient transfusions, novel approaches capable of attrib-
uting inpatient hospitalizations to the need for RBC trans-
fusions to manage anemia in chronic kidney disease are
needed. Likewise, we cannot directly measure savings
attributed to less use of ESAs, since ESA costs are now
subsumed in the PPS. Also, as stated, the introduction of
the PPS coincided with an ESA label change, and we can-
not determine how much of the changes we observed
were due to introduction of the PPS or to the label change
or other factors. Also, as an observational study, this study
cannot definitively determine causality. For example, it is
uncertain whether RBC transfusions are being adminis-
tered to acutely ill patients in EDs because of changes in
anemia practice patterns or for other reasons. Our study
was not designed to address the potential impact of these
changes on outcomes such as mortality and cardiovascular
events. It may well be the case that recent changes in
anemia management have had a beneficial effect on mor-
bidity and mortality in dialysis patients; this issue awaits
more definitive study. We also did not undertake specific
case-mix adjustment in this analysis. Review of United
States Renal Data System data suggests that the distribu-
tion of causes of ESRD, the mean age at dialysis initiation,
and the spectrum of comorbidity burden did not change
materially over this period, making potential changes in
case mix unlikely to explain our findings. Finally, our find-
ings are limited to patients who were covered by Medicare
Parts and A and B and who were dialyzing in facilities that
fully opted in to the PPS at the earliest opportunity.
Conclusions
In conclusion, the introduction of the expanded PPS ap-
pears to be associated with less ESA and IV iron use, lower
hemoglobin concentrations, and greater use of RBC trans-
fusions. Overall Medicare payments to dialysis facilities
appear to have decreased modestly. However, transfusion
use has increased in both the outpatient setting (including
ED visits and observation stays, which are billed as out-
patient visits when patients are not subsequently admitted)
and the inpatient setting. While we cannot definitively
determine whether inpatient transfusion costs borne by the
hospitals have increased, it appears likely that the PPS has
been associated with cost shifting from dialysis facilities to
hospital-based environments. No conclusions can be drawn
from this study as to whether this treatment approach has
benefitted or harmed patients receiving maintenance dialy-
sis. Necessary and important future attempts to control
costs should proceed with an understanding that a reduc-
tion in potentially avoidable interventions and a shift to-
ward use of less-costly and less-acute health care settings
are also important goals.
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